卫光生物(002880) - 2025 Q1 - 季度财报

Financial Performance - Revenue for Q1 2025 was CNY 225,002,020.97, a decrease of 0.57% compared to CNY 226,302,459.95 in the same period last year[5] - Net profit attributable to shareholders was CNY 43,768,169.85, down 6.54% from CNY 46,831,857.32 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.1930, reflecting a decrease of 6.54% compared to CNY 0.2065 in the prior year[5] - Total operating revenue for the current period was ¥225,002,020.97, a decrease of 0.57% from ¥226,302,459.95 in the previous period[18] - Net profit for the current period was ¥43,723,532.62, down 6.4% from ¥46,793,784.04 in the previous period[19] - The total comprehensive income for the current period is CNY 43,723,532.62, compared to CNY 46,793,784.04 in the previous period, reflecting a decrease of approximately 4.5%[20] Cash Flow - Net cash flow from operating activities improved significantly to CNY 21,232,808.69, a 281.18% increase from a negative CNY 11,719,385.39 in the previous year[5] - Cash inflows from operating activities totaled CNY 266,502,826.78, an increase of approximately 16.9% from CNY 227,799,769.87 in the previous period[22] - Cash inflows from investing activities amounted to CNY 55,360,205.56, while cash outflows were CNY 30,351,184.34, resulting in a net cash flow of CNY 25,009,021.22, compared to a net outflow of CNY 46,345,234.02 in the previous period[22] - Cash inflows from financing activities were CNY 100,000,000.00, down from CNY 154,378,416.90 in the previous period, reflecting a decrease of about 35.2%[22] - The net cash flow from financing activities is -CNY 15,911,820.57, a significant decline compared to a net inflow of CNY 142,930,683.34 in the previous period[22] - The ending cash and cash equivalents balance is CNY 305,060,446.40, down from CNY 336,343,535.12 in the previous period, indicating a decrease of approximately 9.3%[22] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 3,290,684,004.06, a slight decrease of 0.21% from CNY 3,297,444,233.19 at the end of the previous year[5] - Total liabilities decreased to ¥1,002,724,006.27 from ¥1,053,207,768.02, a reduction of 4.8%[16] - The company's equity attributable to shareholders increased to ¥2,255,193,500.99 from ¥2,211,425,331.14, an increase of 1.97%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,540[10] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares[10] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 1,197,892.46, contributing positively to the financial results[7] - Other income increased by 44.79% to CNY 2,284,038.25, primarily due to an increase in government subsidies received[8] - Research and development expenses were ¥11,551,806.32, down 5.5% from ¥12,223,999.54 in the previous period[19] - The company reported a credit impairment loss of ¥343,987.15, compared to a loss of ¥503,396.46 in the previous period[19] Accounting and Audit - The company has not undergone an audit for the first quarter report[23] - The company will implement new accounting standards starting from 2025[24]